Konfluan Papilomatoz Retikule (Confluent reticulated papillomatosis) se yon maladi dèrmatoz ichthyosiform akeri ki pa komen, men ki diferan, ki karakterize pa plak ki pèsistan, fè nwa, kal, epi ki gen tandans pou lokalize sitou sou kòf santral la. Maladi a ka trete ak Minocycline.
Confluent and reticulated papillomatosis of Gougerot and Carteaud is an uncommon but distinctive acquired ichthyosiform dermatosis characterized by persistent dark, scaly, papules and plaques that tend to be localized predominantly on the central trunk.
☆ AI Dermatology — Free Service Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Ka tipik — li parèt kòm yon tach pigman nwa ki pa gen okenn sentòm (demanjezon, doulè) alantou ren an.
Confluent and reticulated papillomatosis (CRP), yo rele tou sendwòm Gougerot‑Carteaud, se yon kondisyon ki rezilta nan kwasans selil po nòmal. Li parèt kòm tach nwa ki pa doulè, ki ka fonn ansanm pou fòme plak pi gwo, souvan sou pwatrin anlè a ak kou, espesyalman lakay adolesan ak jèn adilt. Premye chwa pou tretman se minocycline. Confluent and reticulated papillomatosis (CRP), also known as Gougerot-Carteaud syndrome, is caused by disordered keratinization. It presents with asymptomatic hyperpigmented papules that can coalesce into plaques and are typically located on the upper trunk and neck of teens and young adults. First-line treatment is oral 'minocycline'.
CRP anjeneralman parèt kòm tach nwa ak plak san sou po a nan kou a, anbaswa, anwo pwatrin, ak sou do a. Pafwa, li ka gaye jiska fwon an epi desann nan zòn pibyen an. Antibyotik tankou minocycline vin tounen yon chwa tretman pi pito. CRP typically presents as asymptomatic hyperpigmented papules and plaques with peripheral reticulation over the nape, axillae, upper chest, and upper back, occasionally with extension superior to the forehead and inferior to the pubic region. Antibiotics, such as 'minocycline', at anti-inflammatory doses have emerged as a preferred therapeutic option.
○ Tretman
Minocycline